title: [Immunological and histological analyses of transarterial immuno-embolization therapy (TIE) in operable patients with hepatocellular carcinoma].
abstract: Immunological and histological analyses were performed on 14 patients with hepatocellular carcinoma treated by transcatheter immunoembolization (TIE) and subsequently by hepatic resection. They were compared with the cases treated by transcatheter arterial embolization (TAE). Exceptionally high plasma levels of inflammatory cytokines, such as IL-6 and IL-8, were noted 3 hours after TIE insults in the majority of the cases. On the contrary, exceptionally high levels of TNF-alpha were also observed in some cases of TIE treatment. In addition, light microscopically, the lytic necrosis of the tumor and massive infiltration of mononuclear cells were the histological characteristics of this treatment. Interestingly, the population of the infiltrates has altered after TIE treatment. It thus consisted mainly of neutrophils in early phase, subsequently of the mixture of lymphocytes, eosinophils, and plasma cells, and finally of lymphocytes. These results may suggest that certain inflammatory responses caused by TIE may play important roles in this new therapeutic modality.
authors.affiliation: Dept. of Surgery II, Osaka University Medical School.
authors.forename: T
authors.initials: T
authors.lastname: Yoshida
authors.forename: T
authors.initials: T
authors.lastname: Kanai
authors.forename: M
authors.initials: M
authors.lastname: Monden
authors.forename: Y
authors.initials: Y
authors.lastname: Kita
authors.forename: M
authors.initials: M
authors.lastname: Sakon
authors.forename: M
authors.initials: M
authors.lastname: Gotoh
authors.forename: K
authors.initials: K
authors.lastname: Umeshita
authors.forename: Y
authors.initials: Y
authors.lastname: Hanike
authors.forename: T
authors.initials: T
authors.lastname: Monden
authors.forename: H
authors.initials: H
authors.lastname: Nakamura
mesh_terms: D006528:Carcinoma, Hepatocellular / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D005340:Fibrinogen / Q000008:administration & dosage*; D006499:Hepatic Artery; D006801:Humans; D015850:Interleukin-6 / Q000097:blood; D016209:Interleukin-8 / Q000097:blood; D008113:Liver Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D016131:Lymphocyte Subsets; D010844:Picibanil / Q000008:administration & dosage*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
chemical_list: D015850:Interleukin-6; D016209:Interleukin-8; D014409:Tumor Necrosis Factor-alpha; D010844:Picibanil; D005340:Fibrinogen